Since there is evidence for an association between altered BDNF signaling and the occurrence and/or intensity of AD pathology, the aim of the present study was to combine these two factors in a novel animal model to study the impact of chronically reduced endogenous BDNF levels on the development of AD pathology in vivo. This evidence concerns the gene BDNF and Alzheimer disease.